Comprehensive translational assessment of human- induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias

Toxicological Sciences

Volumn 155, Issue 1, 2017, Pages 234-247

  Blinova, Ksenia ^a   Stohlman, Jayna ^a   Vicente, Jose ^a,b,c   Chan, Dulciana ^a   Johannesen, Lars ^a   Hortigon Vinagre, Maria P ^d,e   Zamora, Victor ^d,e   Smith, Godfrey ^d,e   Crumb, William J ^f   Pang, Li ^g   Lyn Cook, Beverly ^g   Ross, James ^h   Brock, Mathew ^h   Chvatal, Stacie ^h   Millard, Daniel ^h   Galeotti, Loriano ^a   Stockbridge, Norman ^b   Strauss, David G ^a,b  

^a CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e BioCity Scotland Newhouse   (United Kingdom)

^f ZENAS TECHNOLOGIES LLC   (United States)

^g NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^h AXION BIOSYSTEMS   (United States)

Author keywords

CiPA; Cor.4U; ICell; IPSC CM; MEA; VSD

Indexed keywords

AMIODARONE; AMITRIPTYLINE; AZITHROMYCIN; BEPRIDIL; CHLOROQUINE; CHLORPROMAZINE; CIBENZOLINE; CISAPRIDE; DILTIAZEM; DOFETILIDE; ION CHANNEL; LIDOCAINE; MEXILETINE; MIBEFRADIL; MOXIFLOXACIN; NILOTINIB; POTASSIUM CHANNEL HERG; PROPAFENONE; QUINIDINE; QUININE; RANOLAZINE; RITONAVIR; SERTINDOLE; TERFENADINE; TOREMIFENE; VERAPAMIL;

ACTION POTENTIAL DURATION; ARTICLE; CARDIAC MUSCLE CELL; CARDIOTOXICITY; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; ELECTRIC POTENTIAL; GENE EXPRESSION; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART TISSUE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL; MICROELECTRODE; PROTEIN EXPRESSION; QT PROLONGATION; TORSADE DES POINTES; CHEMICALLY INDUCED; CYTOLOGY; TRANSLATIONAL RESEARCH;

ARRHYTHMIAS, CARDIAC; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85014406477     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfw200     Document Type: Article

References (48)

1. (2005a). International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed. Regist. 70, 61134-61135.
2. (2005b). International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. Fed. Regist. 70, 61133-61134.
3. Antzelevitch, C., Belardinelli, L., Zygmunt, A. C., Burashnikov, A., Di Diego, J. M., Fish, J. M., Cordeiro, J. M., and Thomas, G. (2004). Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904-910.
4. Asakura, K., Hayashi, S., Ojima, A., Taniguchi, T., Miyamoto, N., Nakamori, C., Nagasawa, C., Kitamura, T., Osada, T., Honda, Y., et al., (2015). Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cellderived cardiomyocytes. J Pharmacol. Toxicol.Methods 75:17-26.
5. Burridge, P., Keller, G., Gold, J., and Wu, J. (2012). Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10, 16-28.
6. Chaitman, B. R., Pepine, C. J., Parker, J. O., Skopal, J., Chumakova, G., Kuch, J., Wang, W., Skettino, S. L., and Wolff, A. A. (2004). Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 291, 309-316.
7. Clements, M., and Thomas, N. (2014). High-throughput multiparameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicol. Sci. 140, 445-461.
8. Colatsky, T., Fermini, B., Gintant, G., Pierson, J. B., Sager, P., Sekino, Y., Strauss, D. G., and Stockbridge, N. (2016). The comprehensive in vitro proarrhythmia assay (CiPA) initiative-update on progress. J. Pharmacol. Toxicol. Methods., doi: 10.1016/j.vascn.2016.06.002.
9. Crumb, W. J., Jr., Pigott, J. D., and Clarkson, C. W. (1995). Description of a nonselective cation current in human atrium. Circ. Res. 77, 950-956.
10. Crumb, W. J., Jr., Vicente, J., Johannesen, L., and Strauss, D. G. (2016). An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. J. Pharmacol. Toxicol. Methods.doi: 10.1016/j.vascn.2016.03.009.
11. Doherty, K. R., Wappel, R. L., Talbert, D. R., Trusk, P. B., Moran, D. M., Kramer, J. W., Brown, A. M., Shell, S. A., and Bacus, S. (2013). Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol. Appl. Pharmacol. 272, 245-255.
12. Fermini, B., Hancox, J. C., Abi-Gerges, N., Bridgland-Taylor, M., Chaudhary, K. W., Colatsky, T., Correll, K., Crumb, W., Damiano, B., Erdemli, G., et al., (2016). A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. J. Biomol. Screen 21, 1-11.
13. Florian, J. A., Tornoe, C. W., Brundage, R., Parekh, A., and Garnett, C. E. (2011). Population pharmacokinetic and concentration-QTc models for moxifloxacin: Pooled analysis of 20 thorough QT studies. J. Clin. Pharmacol. 51, 1152-1162.
14. Fridericia, L. S. (2003). The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann. Noninvasive Electrocardiol. 8, 343-351.
15. Gibson, J. K., Yue, Y., Bronson, J., Palmer, C., and Numann, R. (2014). Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents. J. Pharmacol. Toxicol. Methods 70, 255-267.
16. Gilead Sciences (2013). I. Ranexa (Ranolazine), label information.
17. Guo, L., Abrams, R. M., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., and Kolaja, K. L. (2011). Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 123, 281-289.
18. Guo, L., Coyle, L., Abrams, R. M., Kemper, R., Chiao, E. T., and Kolaja, K. L. (2013). Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol. Sci. 136, 581-594.
19. Harris, K., Aylott, M., Cui, Y., Louttit, J. B., McMahon, N. C., and Sridhar, A. (2013). Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 134, 412-426.
20. Hernandez, D., Millard, R., Sivakumaran, P., Wong, R. C., Crombie, D. E., Hewitt, A. W., Liang, H., Hung, S. S., Pebay, A., Shepherd, R. K., et al., (2016). Electrical stimulation promotes cardiac differentiation of human induced pluripotent stem cells. Stem Cells Int. 2016, 1718041.
21. Hoekstra, M., Mummery, C. L., Wilde, A. A., Bezzina, C. R., and Verkerk, A. O. (2012). Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front. Physiol. 3, 346.
22. Johannesen, L., Vicente, J., Mason, J. W., Erato, C., Sanabria, C., Waite-Labott, K., Hong, M., Lin, J., Guo, P., Mutlib, A., et al., (2016). Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial. Clin. Pharmacol. Ther. 99, 214-223.
23. Johannesen, L., Vicente, J., Mason, J. W., Sanabria, C., Waite-Labott, K., Hong, M., Guo, P., Lin, J., Sorensen, J. S., Galeotti, L., et al., (2014). Differentiating drug-induced multichannel block on the electrocardiogram: Randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin. Pharmacol. Ther. 96, 549-558.
24. Kattman, S. J., Witty, A. D., Gagliardi, M., Dubois, N. C., Niapour, M., Hotta, A., Ellis, J., and Keller, G. (2011). Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8, 228-240.
25. Kim, C., Majdi, M., Xia, P., Wei, K. A., Talantova, M., Spiering, S., Nelson, B., Mercola, M., and Chen, H. S. (2010). Non-cardiomyocytes influence the electrophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation. Stem Cells Dev. 19, 783-795.
26. Knollmann, B. C. (2013). Induced pluripotent stem cell-derived cardiomyocytes: Boutique science or valuable arrhythmia model? Circ. Res. 112, 969-976.
27. Kolb, C., Ndrepepa, G., and Zrenner, B. (2008). Late dofetilideassociated life-threatening proarrhythmia. Int. J. Cardiol. 127, e54-e56.
28. Kramer, J., Obejero-Paz, C. A., Myatt, G., Kuryshev, Y. A., Bruening-Wright, A., Verducci, J. S., and Brown, A. M. (2013). MICE models: Superior to the HERG model in predicting Torsade de Pointes. Sci. Rep. 3, 2100.
29. Kuryshev, Y. A., Ficker, E., Wang, L., Hawryluk, P., Dennis, A. T., Wible, B. A., Brown, A. M., Kang, J., Chen, X. L., Sawamura, K., et al., (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 312, 316-323.
30. Laflamme, M. A., Chen, K. Y., Naumova, A. V., Muskheli, V., Fugate, J. A., Dupras, S. K., Reinecke, H., Xu, C., Hassanipour, M., Police, S., et al., (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotech. 25, 1015-1024.
31. Lewis, K. J., Silvester, N. C., Barberini-Jammaers, S., Mason, S. A., Marsh, S. A., Lipka, M., and George, C. H. (2015). A new system for profiling drug-induced calcium signal perturbation in human embryonic stem cell-derived cardiomyocytes. J. Biomol. Screen 20, 330-340.
32. Lu, Z., Wu, C. Y., Jiang, Y. P., Ballou, L.M., Clausen, C., Cohen, I. S., and Lin, R. Z. (2012). Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl. Med 4, 131ra50.
33. Ma, J., Guo, L., Fiene, S. J., Anson, B. D., Thomson, J. A., Kamp, T. J., Kolaja, K. L., Swanson, B. J., and January, C. T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006-H2017.
34. Maddah, M., Heidmann, J. D., Mandegar, M. A., Walker, C. D., Bolouki, S., Conklin, B. R., and Loewke, K. E. (2015). A noninvasive platform for functional characterization of stemcell-derived cardiomyocytes with applications in cardiotoxicity testing. Stem Cell Rep. 4, 621-631.
35. Nagra, B. S., Ledley, G. S., and Kantharia, B. K. (2005). Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderlyman taking dofetilide for atrial fibrillation: A cautionary tale. J. Cardiovasc. Pharmacol. Ther. 10, 191-195.
36. Navarrete, E. G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P. W., Patlolla, B., Lee, A. S., et al., (2013). Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 128(11 Suppl 1), S3-13.
37. Pfizer (1999). Tikosyn (Dofetilide), label information.
38. Pharm. Res. Assoc. (1999). Cardioquin (Quinidine Polygalacturonate), label information.
39. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., et al., (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45.
40. Reiffel, J. A. (2005). Atypical proarrhythmia with dofetilide: Monomorphic VT and exercise-induced torsade de pointes. Pacing Clin. Electrophysiol. 28, 877-879.
41. Sager, P. T., Gintant, G., Turner, J. R., Pettit, S., and Stockbridge, N. (2014). Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 167, 292-300.
42. Stockbridge, N., Morganroth, J., Shah, R. R., and Garnett, C. (2013). Dealing with global safety issues: Was the response to QTliability of non-cardiac drugs well coordinated? Drug Saf. 36, 167-182.
43. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872.
44. Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
45. Talajic, M., DeRoode, M. R., and Nattel, S. (1987). Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: Evidence for clinically relevant activity of the metabolite. Circulation 75, 265-271.
46. Wroblewski, H. A., Kovacs, R. J., Kingery, J. R., Overholser, B. R., and Tisdale, J. E. (2012). High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis. Antimicrob. Agents. Chemother. 56, 4495-4499.
47. Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al., (2008). Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453, 524-528.
48. Yang, T., Chun, Y. W., Stroud, D. M., Mosley, J. D., Knollmann, B. C., Hong, C., and Roden, D. M. (2014). Screening for acute IKr block is insufficient to detect torsades de pointes liability: Role of late sodium current. Circulation 130, 224-234.